Lilly Announces Details of Presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
News provided by
Share this article
Share this article
INDIANAPOLIS, May 19, 2021 /PRNewswire/ New data from across Eli Lilly and Company s (NYSE: LLY) oncology portfolio will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 4-8, 2021. The data include new analyses of Verzenio
® (abemaciclib) from the Phase 3 monarchE trial in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC) with a high risk of recurrence who received neoadjuvant chemotherapy. In addition, the first clinical data from the Phase 1 study of Lilly s oral selective estrogen receptor degrader (SERD) will be presented at the meeting.
Lilly Announces Details of Presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Published: Jan 25, 2021
(margetuximab-cmkb)
trastuzumab), both with chemotherapy
In the U.S., MARGENZA is approved, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease
ROCKVILLE, MD, Jan. 25, 2021 (GLOBE NEWSWIRE) MacroGenics, Inc.. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the publication of results from the SOPHIA trial of MARGENZA™ (margetuximab-cmkb) in the
Journal of the American Medical Association (JAMA) Oncology. SOPHIA is a pivotal Phase 3 clinical trial of 536 adult patients with metastatic HER2-positive breast cancer previously treated with two or more anti-HER2 regimens and from one to three lines of therapy for metastatic disease. In the study, MARGENZA
Search jobs FDA Approves Amgen s RIABNI(TM) (rituximab-arrx), A Biosimilar To Rituxan® (rituximab)
THOUSAND OAKS, Calif., Dec. 17, 2020 /PRNewswire/ Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan
® (rituximab), for the treatment of adult patients with Non-Hodgkin s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA) (Wegener s Granulomatosis), and Microscopic Polyangiitis (MPA). RIABNI will be made available in the U.S. in January 2021. The approval of RIABNI represents an important milestone across our biosimilar and oncology portfolios, said Murdo Gordon, executive vice president of Global Commercial Operations at Amgen. Following the proven success of KANJINTI
Amgen today announced that the U.S. Food and Drug Administration has approved RIABNI™ a biosimilar to Rituxan ® for the treatment of adult patients with Non-Hodgkin’s Lymphoma Chronic Lymphocytic Leukemia Granulomatosis with Polyangiitis and Microscopic Polyangiitis . RIABNI will be made available in the U.S. in January 2021 . “The approval of RIABNI represents an important milestone across our biosimilar and …
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan ® (rituximab), for the treatment of adult patients with Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis), and Microscopic Polyangiitis (MPA). RIABNI will be made available in the U.S. in January 2021 .
vimarsana © 2020. All Rights Reserved.